All HHS Contracts — March 25, 2026

Two awards totaling $928M (78% of period value) to Elevance and Emergent provide steady cash flows with $515M already outlayed and performance to 2027+.

$262M to nonprofits with $178M outlayed supports CMS/NIH programs through 2026-27 but offers no profit fees or shareholder upside.

All contracts extend to 2026-27+ with $674M remaining outlays, exposing to termination, delays, or programmatic shifts.

High subawards ($207M across 345 subs, avg 17% of obligations) create subcontractor dependencies and margin pressure.

Cost-plus/award-fee (50% of value) and firm-fixed-price structures risk profitability from overruns or evaluations.

$284M unexercised options (24% of total value) in Emergent and Mount Sinai contracts could extend revenue to 2029.

CMS IT modernization and ASPR biostockpiling via $928M awards signal sector tailwinds for scalable for-profit providers.

CMS awards 55% of value ($660M) for IT systems and program support, fully obligated through 2026-27.

ASPR/NIH fund $530M (45% of value) for antivirals/vaccines with extensions to 2029 potential.

{"entity"=>"Elevance Health", "reason"=>"Largest award ($505M, 42% of period) with $259M outlayed signals CMS IT revenue base.", "trigger"=>"outlays >$350M or 2027 termination notice"}

{"entity"=>"Emergent BioSolutions", "reason"=>"$422M obligated + $284M options in non-competed ASPR contract for VIGIV.", "trigger"=>"option exercise to unlock $706M ceiling"}

{"entity"=>"HHS subawards network", "reason"=>"345 subs totaling $207M (17% of value) across awards indicate subcontracting ecosystem.", "trigger"=>"prime margins eroding below 20% retention"}